Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

News Features

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

October 17, 2022

Pascal TEER Device Performs Well in Patients With Complex Anatomy

News Conference News TCT 2022

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Yael L. Maxwell

September 26, 2022

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

News Conference News TCT 2022

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

Yael L. Maxwell

September 18, 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

News Conference News TCT 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

September 18, 2022

Clinical Benchmarks for Therapy Success in Transcatheter Tricuspid Therapy

Presentation TCT 2022

Clinical Benchmarks for Therapy Success in Transcatheter Tricuspid Therapy

Presenter: David Cohen

September 17, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

Novel Digital Approaches to Aortic Valve Disease Screening: Introduction to the PREVUE VALVE Study

Presentation TVT 2022

Novel Digital Approaches to Aortic Valve Disease Screening: Introduction to the PREVUE VALVE Study

Presenter: David J. Cohen

June 09, 2022

Flash Proposal: A Novel Bicuspid TAVR Trial in the Modern Era

Presentation TVT 2022

Flash Proposal: A Novel Bicuspid TAVR Trial in the Modern Era

Presenter: David Cohen

June 08, 2022

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

News Daily News

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

Michael O'Riordan

March 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.